Results 251 to 260 of about 113,461 (351)
ABSTRACT The rise in cancer, autoimmune, inflammatory, and infectious diseases in recent decades has led to a surge in the development of monoclonal antibodies (mAbs) therapies, now the most widely used family of biologics. To meet the growing global demand, biopharmaceutical industries are intensifying their production processes.
Ilona Metayer +7 more
wiley +1 more source
Integrated SegFlow, µSIA, and UPLC for Online Sialic Acid Quantitation of Glycoproteins Directly from Bioreactors. [PDF]
Chemmalil L +12 more
europepmc +1 more source
This study explores how antigen peptides and sugar chains affect the efficacy of glyco‐nanovaccines (iGN) in cancer immunotherapy. We show that antigen peptides, rather than sugar chains, are key to nanoparticle uptake and immune activation, with sialic acid‐modified iGN showing similar anti‐cancer efficacy to α‐mannose‐modified iGN in a mouse model ...
Narumi Harada +10 more
wiley +1 more source
Profiling the regulatory landscape of sialylation through miRNA targeting of CMP- sialic acid synthetase. [PDF]
Jame-Chenarboo F +3 more
europepmc +1 more source
Estrogen Modulation of B Cell Immunity: Implications for HIV Control and Therapeutic Strategies
Estrogen significantly modulates B‐cell immunity. We provide evidence for estrogen–B‐cell crosstalk (the estrogen–B‐cell axis) in regulating B‐cell function and shaping HIV acquisition, progression, and persistence, and highlight research gaps to guide hormone‐aware vaccines and therapies.
John Kasibante +3 more
wiley +1 more source
RETRACTION: Synthesis and Cardiovascular Protective Effects of Quercetin 7-O-Sialic Acid. [PDF]
europepmc +1 more source
Dysbiosis-associated gut bacterium <i>Ruminococcus gnavus</i> varies at the strain level in its ability to utilize key mucin component sialic acid. [PDF]
Sokolovskaya OM +8 more
europepmc +1 more source
Pharmacodynamic (PD) biomarkers can support biosimilarity assessment, potentially reducing the need for comparative clinical efficacy studies. This study aimed to characterize previously identified proteomic PD biomarker candidates for Interferon beta‐1a (IFNβ‐1a, n = 248) and pegylated IFNβ‐1a (pegIFNβ‐1a, n = 528) biologics at therapeutic doses, to ...
Lakshmi Manasa S. Chekka +15 more
wiley +1 more source

